NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX ), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

Shares of IMUX stock opened at $1.07 on Tuesday. The firm has a market cap of $95.93 million, a price-to-earnings ratio of -0.87 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 ...

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's ...

Plus, a first-quarter stock and bond market wrap up. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...